Horizon Technology Finance Logo
US44045A1025
A1C8VS
HRZN

Horizon Technology Finance

Loading quotes...

Forecast

The analysts' average price target is +3,97 (6,81%). The median is +3,97 (6,81%).

Buy
  5
Hold
  15
Sell
  2

  • Horizon Technology Finance Q2: NAV falls after Soli write-downs despite portfolio growth post‑Monroe merger

    Horizon Technology Finance reported NAV of $6.23, down from $6.98, primarily due to a $20 million equity write‑off and $19 million debt write‑down related to Soli. The company expanded its debt portfolio to $682 million, funded nine debt investments totaling $73 million, and increased its committed backlog to $228 million following the Monroe merger. Q2 net investment income was $0.11 per share ($0.18 excluding one‑time merger costs); Horizon ended the quarter with $229 million in liquidity, $459 million of potential investment capacity, repurchased 1.4 million shares and authorized an additional $20 million buyback. Management expects continued portfolio growth and aims for net investment income to cover distributions over time. » More on finance.yahoo.com


  • Horizon Technology Finance completes Monroe merger, reports portfolio growth and strong yield

    Horizon Technology Finance closed its merger with Monroe Capital and formed the RoHo joint venture with ROTH Capital to finance small and micro-cap public companies. Assets rose to $696 million with $120 million of life-science originations in Q1, a debt portfolio yield of about 15.2%, net investment income of $0.19 per share and NAV of $6.98. The company has $105 million of available liquidity, net leverage of 1.13-to-1 and a committed backlog of $180 million, and plans a $10 million share repurchase. The board declared regular monthly distributions of $0.06 and special monthly distributions of $0.03 for July through September 2026. » More on finance.yahoo.com


  • Horizon Technology Finance completes merger with Monroe Capital

    Horizon Technology Finance has completed its merger with Monroe Capital and will continue as the surviving company. On a pro forma basis the combined company has net assets of approximately USD 471.7 million and about USD 141.1 million in cash, which will be used partly to repay liabilities and for new investments. Horizon issued 20,370,693 new common shares; former MRCC shareholders hold 29.86% and Horizon shareholders 70.14% of the merged company. MRCC shareholders will receive a cash payment of USD 0.60 per share; Horizon also plans to use taxable gains to supplement distributions for the first two quarters after the merger and to defer management fees of up to USD 4 million over four quarters. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics
In 2026, Horizon Technology Finance has already paid +0,59 in dividends. The last payout was in August.

Financials

In the last quarter, Horizon Technology Finance had revenue of +16.58m and net profit of 32.65m
(EUR) Jun 2026
YoY
Revenue +16.58m 297,62%
Gross profit +13.45m 187,63%
Net profit 32.65m 85,22%
EBITDA 25.82m 54,27%

Fundamentals

Metric Value
Market capitalization
+205.86m
Number of shares
50.08m
52-week high/low
+6,07 - +3,26
Dividend yield
+23,58%
Dividends TTM
+0,97
Next dividend
+0,0772
Beta
0,97
P/E ratio
+12,01
PEG ratio
+0,01
P/B ratio
+0,75
P/S ratio
+2,32

Company profile

Horizon Technology Finance Corporation ist eine Unternehmensentwicklungsgesellschaft, die sich auf die Vergabe von Krediten und Investitionen in der Entwicklungsphase spezialisiert hat. Sie konzentriert sich auf die Vergabe von besicherten Krediten und Risikokrediten an mit Risikokapital finanzierte Unternehmen in den Bereichen Technologie, Biowissenschaften, Gesundheitsinformationen und -dienstleistungen sowie Cleantech. Sie versucht, in Unternehmen in den Vereinigten Staaten zu investieren.

Name
Horizon Technology Finance
CEO
Michael Phillip Balkin
Headquarters Farmington, ct
USA
Website
Sector
Financials
Industry
Financial Services
IPO
10/29/2010

Ticker symbols

Exchange Symbol
NASDAQ
HRZN
🍪

Parqet  uses cookies. Learn more